Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Advances in Diagnosis and Targeted Therapy of G719X/L861Q/S768I Mutant  Non-small Cell Lung Cancer].

Zhongguo fei ai za zhi = Chinese journal of lung cancer - 20 Aug 2024

Wang Yufang, Zheng Jing, Zhu Yanping, Zhou Jianya

Abstract excerpt

Lung cancer accounts for the highest proportion of cancer deaths in the world and poses a great threat to human health. About 30% to 40% of non-small cell lung cancer (NSCLC) is caused by point mutations, exon insertion and exon deletion of the epidermal growth factor receptor (EGFR). In addition to the common exon 19 deletion mutation and exon 21 L858R mutation, exon 18 G719X mutation, exon 21 L861Q mutation and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39318252
DOI: 10.3779/j.issn.1009-3419.2024.101.20
PMCID: PMC11425681

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Advances in Diagnosis and Targeted Therapy of G719X/L861Q/S768I Mutant Non-small Cell Lung Cancer].PMID 39318252Read ↗

[Advances on driver oncogenes of non-small cell lung cancer].Semantic proximity Read ↗

Epidermal growth factor receptor mutation testing: From conventional to real-time diagnosis of lung cancer.Semantic proximity Read ↗

Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.Semantic proximity Read ↗

[Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].Semantic proximity Read ↗

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments.Semantic proximity Read ↗

[Emerging biomarker for immunotherapy of non-small cell lung cancer: tumor mutation burden (TMB) and latest progress in related research field].Semantic proximity Read ↗

[Application strategies of the third-generation EGFR-TKI in the context of precision medicine].Semantic proximity Read ↗

Paradigm shift in the management of metastatic Non-small Cell Lung CancerSemantic proximity Read ↗

[Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China].Semantic proximity Read ↗

[Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC].Semantic proximity Read ↗

[Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].Semantic proximity Read ↗

[Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.